[Study on the relationship between PS2 protein expression and prognosis in invasive breast carcinoma].
To study the relationship between the expression of PS2 protein and prognosis in the invasive breast cancer (IBC). Using LSAB immunohistochemical method, PS2 protein expression in 86 cases of IBC was detected. The positive rate of PS2 protein was 66.27% (57/86) in 86 cases of IBC. Under the following 3 conditions, PS2 protein expression levels in the more-than-5-year-survival group (A) were higher than those in the less-than-5-year-survival group (B). (1) In 86 cases of IBC, the expression level was 80.55% (29/36) for Group A, Significantly different from the 56.00% (28/50) of Group B (P < 0.025). (2) In 62 cases of premenopausal patients, the corresponding data were 86.20% (25/29) and 54.54% (18/33) respectively, P < 0.005; whereas in 24 cases of postmenopausal patients, 4/7 and 58.82% (10/17) respectively, P > 0.5. (3) In 62 cases of axillary node positive patients, the expression levels for Groups A and B were 82.35% (14/17) and 55.55% (25/45) respectively, P < 0.05; while in 24 cases of axillary node negative patients, 78.94% (15/19) and (3/5) respectively, P > 0.5. These results suggest that the expression of PS2 protein was positively correlated with 5-year-survival in IBC, and could be considered as a prognostic predictor for breast cancer, PS2 protein expression was a useful indicator for endocrine therapy in premenopausal patients. In axillary node positive patients, the expression of PS2 protein was associated with a better prognosis.